• Save
  • Cite
  • Citation Alert
  • Share

Consensus. Chinese Consensus on Combination Therapy of Chronic Hepatitis B

Professional Staff Committee of Combination Therapy of Chronic Hepatitis B

Jun Cheng1
View More View Less
1 Beijing, China
Volume/Issue:
Volume 1: Issue 1
Published:
27 May 2017
Page Count:
58–64
DOI:
https://doi.org/10.1515/ii-2017-0009
Open access
Keywords:

References

  • 1 Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996;334:1422-1427.

  • 2 Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-1531.

  • 3 Di MV, Marzano A, Lampertico P, Andreone P. Santantonio T. Almasio PL, et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 2004;40: 883-891.

  • 4 Wang L, Yan J, Zhang Z, Wang J, Du Y, Li X, et al. Occurrence and predictive factors of hepatitis B virus polymerase YMDD variation among patients with chronic hepatitis B and liver cirrhosis during lamivudine therapy. C J Hepotol 2004;12:14-17.

  • 5 Zoulim F, Perrillo R. Hepatitis B: reflections on the current approach to antiviral therapy. J Hepatol 2008;48 (Suppl 1):s2-s19.

  • 6 Lampertico P, Vigano M, Manenti E, Iavarone M, Sablon E, Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007;133:1445-1451.

  • 7 Yang YD, Zheng L, Jie HY. De novo lamivudine and adefovir dipivoxil combination therapy for patients with decompensated cirrhosis resulting from chronic hepatitis B. Hepatol Int 2010;4:134.

  • 8 Wan M. The present situation and pondering on antiviral therapy in patients with decompensated cirrhosis. C J Hepotol 2010;18:483-485.

  • 9 Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann HW, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005;129:528-536.

  • 10 Lok AS, Trinh H, Carosi G, Akarca U, Gadano A, Habersetzer F, et al. Entecavir (ETV) monotherapy for 96 weeks is comparable to combination therapy with ETV plus tenofovir (TDF) in nucleos(t)idenaive patients with chronic hepatitis B (CHB): the BE-LOW study. 2011. AASLD.

  • 11 Keeffe EB, Zeuzem S, Koff RS, Dieterich DT, Esteban-Mur R, Gane EJ, et al. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 2007;5:890-897.

  • 12 Chinese Roadmap Expert Group for Telbivudine Treatment. Chinese roadmap for treating chronic hepatitis B with telbivudine. C J Hepotol 2008;16:323-325.

  • 13 Liaw YF. On-treatment outcome prediction and adjustment during chronic hepatitis B therapy: now and future. Antivir Ther 2009;14(1):13-22.

  • 14 Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007;357:2576-2588.

  • 15 Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-662.

  • 16 European Association For The Study Of The Live. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-242.

  • 17 Committee of experts on antiviral therapy of chronic hepatitis C. Experts consensus on antiviral therapy of chronic hepatitis C. C J Exp Clin Infect Dis (Electro Edi) 2009;3:343-352.

  • 18 Sherman M. Strategies for managing coinfection with hepatitis B virus and HIV. Cleve Clin J Med 2009;76(Suppl 3):S30-S33.

  • 19 Xie W, Shi G, Zhang H, Zhao G, Yu Z, Lang Z, et al. A randomized, multi-central, controlled study of patients with hepatitis B e antigenpositive chronic hepatitis B treated by adefovir dipivoxil or adefovir dipivoxil plus bicyclol. Hepatol Int 2012;6:441-448.

  • 20 Qin G, Shi G, Song Y, Chen M. Meta-analysis of document on diammonium Glycyrrhizinate in treatment of patients with chronic hepatitis B. C J Infect Dis 2005;23:333-337.

  • 21 Xia Y, Liu J. Glycyrrhizin and derivatives for treatment of chronic hepatitis B:A systematic review of randomized controlled trials. C J Integr Tradit West Med Liver Dis 2007;17:304-309.

  • 22 Bao F, Xie J. Combination therapy of milk thistles and interferon on hepatitis B. J Qiqihar Univer Med 2006;27:1185-1186.

  • 23 Gou W, Wang Y. Combination therapy of milk thistles and interferon α-2b on hepatitis B. J Clin Hepatol 2004;20:302.

  • 24 Wong DK, Cheung AM, O’ Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993;119:312-323.

  • 25 Harris JM, Martin NE, Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 2001;40:539-551.

  • 26 Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352:2682-2695.

  • 27 Sarin SK, Sood A, Kumar M, Arora A, Amrapurkar D, Sharma BC, et al. Effect of lowering HBV DNA levels by initial antiviral therapy before adding immunomodulator on treatment of chronic hepatitis B. Am J Gastroenterol 2007;102:96-104.

  • 28 Chan HL, Leung NW, Hui AY, Wong VW, Liew CT, Chim AM, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha 2b and lamivudine with lamivudine alone. Ann Intern Med 2005;142:240-250.

  • 29 Wong VW, Wong GL, Yan KK, Chim AM, Chan HY, Tse CH, et al. Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010;51:1945-1953.

  • 30 Fried MW, Piratvisuth T, Lau GK, Marcellin P, Chow WC, Cooksley G, et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 2008;47:428-434.

  • 31 Moucari R, Mackiewicz V, Lada O, Ripault MP, Castelnau C, Martinot-Peignoux M, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009;49:1151-1157.

  • 32 Brunetto MR, Moriconi F, Bonino F, Lau GK, Farci P, Yurdaydin C, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009;49:1141-1150.

  • 33 Wan M, Wong X. Suggestion on chronic hepatitis B with interferon (2010). C J Infect Dis 2010;28:193-200.

  • 34 Vassiliadis T, Tziomalos K, Patsiaoura K, Zagris T, Giouleme O, Soufleris K, et al.Lamivudine/pegylated interferon alfa-2b sequential combination therapy compared with lamivudine monotherapy in HBeAg-negative chronic hepatitis B. J Gastroenterol Hepatol 2007;22:1582-1588.

  • 35 Cao Z, Zhang Y, Ma L, Sun G, He Z, Liu Y, et al. Treatment of HBeAg-positive CHB infection with peginterferon alfa-2a [40KD] puls lamivudine or adefovir for 96 weeks resulting in high rate of HBsAg clearance seroconversion rates. 2010. AASLD.

  • 36 Zafar S, Haque IU, Rehman AU,, et al. Comparison of adefovir and standard interferon combination with standard interferon or adefovir for treatment of chronic hepatitis B. Pakistan J Gastroenterol 2009;23:9-15.

  • 37 Wursthorn K, Lutgehetmann M, Dandri M, Volz T, Buggisch P, Zollner B, et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006;44:675-684.

  • 38 Ma W, Zhou B, Ao F, Zhou D, Hu Y, He Q, et al. Higher sustained post-treatment virologic response following peginterferon alfa-2a ± adefovir compared with adefovir monotherapy in HBeAg-positive patients. 2009. AASLD.

  • 39 Takkenberg B, Zaaijer H, Weegink C, Terpstra V, Dijkgraaf M, Jansen1 P, et al. Baseline HBsAg level predict HBsAg loss in CHB patients treated with a combination of peginterferon alfa-2a and adefovir: an interim analysis. 2009. EASL.

  • 40 Canada H. Risk of peripheral neuropathy in patients treated with telbivudine (SEBIVO) and interferon- For Health Professionals. (Accessed at http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/_2008/sebivo_hpc-cps-eng.php).

  • 41 European Medicines Agency. Risk of peripheral neuropathy with Sebivo (telbivudine). Media Release 2008;2:14.

  • 42 Liu M, Yi W, Cai H. Myositis and peripheral neuropathy associated with telbivudine and interferon. Adver Drug React J 2010;12:130-131.

  • 43 Baumann CA, Badamchian M, Goldstein AL. Thymosin alpha 1 antagonizes dexamethasone and CD3-induced apoptosis of CD4+CD8+ thymocytes through the activation of cAMP and protein kinase C dependent second messenger pathways. Mech Ageing Dev 1997;94:85-101.

  • 44 Loggi E, Gramenzi A, Margotti M, Cursaro C, Galli S, Vitale G, et al. In vitro effect of thymosin-alpha1 and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with eAg-negative chronic hepatitis B. J Viral Hepat 2008;15:442-448.

  • 45 Lim SG, Wai CT, Lee YM, Dan YY, Sutedja DS, Wee A, et al. A randomized, placebo-controlled trial of thymosin-alpha1 and lymphoblastoid interferon for HBeAg-positive chronic hepatitis B. Antivir Ther 2006;11:245-253.

  • 46 Mao H, Shi T. Treatment with interferon and thymosin alpha-1 versus interferon monotherapy for HBeAg positive chronic hepatitis B: a Meta-analysis. C J Hepatol 2011;19:29-33.

  • 47 Zhang Y, Chen E, Yang J, Duan Y, Tang H. Treatment with lamivudine versus lamivudine and thymosin alpha-1 for e antigen-positive chronic hepatitis B patients: a meta-analysis. Virol J 2009;6:63.

Infection International

Infection International
Volume 1: Issue 1

Journal Information

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 23 23 22
PDF Downloads 5 5 5